Searchable abstracts of presentations at key conferences in endocrinology
Previous issue | Volume 41 | ECE2016 | Next issue

18th European Congress of Endocrinology

Oral Communications


ea0041oc5.1 | Neuroendocrinology | ECE2016

The Drosophila AIP orthologue is essential for actin cytoskeleton stabilisation and cell adhesion

Aflorei Elena Daniela , Klapholz Benjamin , Moderau Nina , Baptista-Ribeiro Paulo , Tapon Nic , Brown Nick , Stanewsky Ralf , Korbonits Marta

Introduction: Tumours with aryl hydrocarbon receptor interacting (AIP) mutations often show an unusually aggressive and invasive clinical course as up to 80% of AIP positive pituitary adenomas have a certain degree of extrasellar extension. The exact mechanisms by which AIP inactivation promotes an aggressive behaviour remain unknown. The majority of adenohypophysis is composed of sinuous cords of epithelial cells and consequently, molecules that can induce remodellin...

ea0041oc5.2 | Neuroendocrinology | ECE2016

Analysis of signal transduction in mice overexpressing mutant versus intact IGFBP-2 identifies a plethora of IGFBP-2 dependent mechanisms in different tissues and suggests permissive or regulatory effects of the RGD-sequence

Hoeflich Andreas , Reyer Anja , Schindler Nancy , Ohde Daniela , Wirthgen Elisa , Brenmoehl Julia

IGFBP-2 represents a multifunctional protein with effects on growth, reproductive development, aging, and metabolism. For the expression of these diverse effects in vivo, IGFBP-2 has a number of binding sites for IGFs, integrins, and proteoglycans. In order to assess the relative contributions of these binding sites to the multiple effects of IGFBP-2, we have developed transgenic mouse models overexpressing intact or mutant IGFBP-2. Here we discuss functions of the RG...

ea0041oc5.3 | Neuroendocrinology | ECE2016

Development of a long-acting growth hormone antagonist for the treatment of acromegaly

Wilkinson Ian , Pradhananga Sarbendra , Speak Rowena , Sayers Jon , Ross Richard

Background: The UK acromegaly register reported that <60% of acromegalics on medical therapy had controlled disease (1). Pegvisomant, a growth hormone antagonist (GHA), controls disease in >95% cases, but is not cost-effective and requires high dose daily injections (2). We have developed a fusion technology for making a cost-effective long-acting GH molecule (3), and generated a GHA by linking mutated growth hormone to its binding protein (GHBP).<p class="abstext"...

ea0041oc5.4 | Neuroendocrinology | ECE2016

CNS IL-6 Trans-Signaling is enhanced in obese mice to improve anorexigenic and glucoregulatory effects of IL-6

Timper Katharina , Denson Jesse , Steculorum Sophie Marie , Rose-John Stefan , Wunderlich Frank Thomas , Bruning Jens C

Introduction: Interleukin (IL)-6 can activate signal transducer and activator of transcription (STAT)3-dependent signaling similar to leptin in neurons. Here we demonstrate that central application of IL-6 suppresses feeding and improves glucose tolerance in mice. Furthermore, we found that central IL-6 trans-signaling is enhanced in obese mice to improve anorexigenic and glucoregulatory effects of IL-6.Methods/design: Glucose tolerance and insulin sensi...

ea0041oc5.5 | Neuroendocrinology | ECE2016

Zebrafish tool for the study of prokineticin receptor 2 (PROKR2) pathway on GNRH3 neuronal development

Bassi Ivan , Marelli Federica , Vezzoli Valeria , Persani Luca , Gothilf Yoav , Bonomi Marco

The G protein-coupled receptor PROKR2 play an important and not fully understood role in GnRH-secreting neurons physiology. Indeed, mutations of PROKR2 in humans are known to cause Congenital Hypogonadotropic Hypogonadism (CHH) although with an important reproductive and olfactory phenotypic heterogeneity. The attempt to mimic PROKR2 human allelic variants in mouse model has so far failed to give insights into the mechanisms involved. The zebrafish (ZF), due to its amenability...